Rhizomucor miehei

Rhizomucor miehei: A Comprehensive Reference

1. Identity, Taxonomy, and Classification

Nomenclature and Synonyms

Rhizomucor miehei (Cooney & R. Emers.) is a thermophilic filamentous fungus belonging to the kingdom Fungi. According to the NCBI Taxonomy Browser, its full lineage places it within the cellular organisms → Eukaryota → Opisthokonta → Fungi → Mucoromycota → Mucoromycotina → Mucoromycetes → Mucorales → Lichtheimiaceae → Rhizomucor. The type material is designated under culture-collection accession numbers including CBS 182.67 and ATCC 16457.

Because the Mucor genus has undergone, and will certainly still undergo, substantial taxonomic changes, the literature reports a large number of erroneous species denominations. Among the most cited, Rhizomucor miehei often appears as Mucor miehei, its former name. This older nomenclature is still encountered throughout scientific and commercial literature, and both names refer to the same organism.

Taxonomic Position within Rhizomucor

The genus Rhizomucor is a cosmopolitan filamentous fungus found in soil and decaying fruit and vegetables. In its current classification, Rhizomucor harbours only thermophilic species with maximum growth temperatures above 50 °C and minimum growth temperatures below 20 °C. These species, including Rm. miehei, Rm. pusillus, Rm. nainitalensis, and Rm. pakistanicus, possess subglobose to short ellipsoidal sporangiospores.

Rhizomucor miehei is homothallic, while Rhizomucor pusillus is homo- or heterothallic. Maximum growth temperature, biochemical assimilation profile, thiamine dependency, and the diameter of the sporangia aid in differentiation of the three Rhizomucor species from each other.

Morphology

Colonies of Rhizomucor grow very rapidly, fill the Petri dish, and mature in approximately four days. The texture is typically cotton-candy-like. From the front, the color of the colony is white initially and turns grey to yellowish-brown in time, while the reverse is white to pale.

The microscopic morphology of Rhizomucor appears to be intermediate between that of Rhizopus and Mucor. Nonseptate or sparsely septate broad hyphae, rudimentary rhizoids, sporangiophores, sporangia, and sporangiospores are visualized. All strains are homothallic, forming numerous zygospores that are reddish-brown to blackish-brown, globose to slightly compressed, up to 50 µm in diameter, with stellate warts and equal suspensor cells. Colony colour is a dirty grey rather than brown, and sporangia have spiny walls up to 50–60 µm in diameter, with columellae rarely larger than 30 µm in diameter. Growth is stimulated by thiamine, with no assimilation of sucrose, and the maximum growth temperature is 54–58 °C.

Rhizomucor species consist of Mucor-like fungi that produce nonapophysate sporangia and branched sporangiophores but, unlike Mucor, they form rhizoids. The genus Rhizomucor is distinguished from Mucor by the presence of stolons and poorly developed rhizoids at the base of the sporangiophores, and by the thermophilic nature of its species.

Thermophilic Character and Growth Range

The zygomycete fungi like Rhizomucor miehei have been extensively exploited for the production of various enzymes. As a thermophilic fungus, R. miehei is capable of growing at temperatures that approach the upper limits for all eukaryotes. Under experimental conditions, this species grows particularly well at temperatures between 24 and 55 °C, and growth becomes negligible below 21 °C or above 57 °C.

Genome

The assembled genome of R. miehei CAU432 is 27.6 million base pairs (Mb), with 10,345 predicted protein-coding genes. Even though it is thermophilic, the G+C content of the whole fungal genome (43.8%) and coding genes (47.4%) are both less than 50%. The genome of R. miehei harbors a large number of genes encoding secreted proteases, consistent with its reputation as a rich producer of proteases. The transcriptome profile also showed that the genes responsible for degrading starch, glucan, protein, and lipid were highly expressed.

2. Natural Sources, Ecology, and Habitat

Rhizomucor is a cosmopolitan filamentous fungus found in soil and decaying fruit and vegetables. While Rhizomucor species are often isolated from fermenting and composting organic matter, they are also rare causes of serious and often fatal infections in humans. These organisms are environmental filamentous fungi usually found around decaying organic material. Their hyphae are very broad, ribbon-like, and have no or rare hyphal septations, branching at 90° angles.

Thermophilic fungi are important producers of thermostable enzymes that can be used in industrial high-temperature bioprocesses. The thermophilic character of R. miehei is not merely an ecological adaptation but also the property that makes its enzymes industrially attractive, since these proteins are inherently more stable at the elevated temperatures used in many manufacturing processes.

3. Common Forms, Preparations, and Commercial Products

Rhizomucor miehei lipase (RML), formerly known as Mucor miehei lipase, is commercially available in both soluble and immobilized form, with very high activity and good stability under diverse conditions including anhydrous organic solvents and supercritical fluids. It is commercially available in both soluble and immobilized forms, for example under the trade name Lipozyme RM IM.

The food enzyme mucorpepsin (EC 3.4.23.23) is produced with the non-genetically modified Rhizomucor miehei strain DSM 29547 by Chr. Hansen. The food enzyme is free from viable cells of the production organism and is intended for use in dairy processing for cheese production.

A further preparation, mucorpepsin (EC 3.4.23.23), is produced with the non-genetically modified Rhizomucor miehei strain FRO by DSM Food Specialties B.V. The enzyme can be chemically modified to produce a thermolabile form. The food enzyme is free from viable cells of the production organism, and is intended for use in three food manufacturing processes: processing of dairy products for the production of (1) cheese, (2) edible rennet casein, and (3) fermented dairy products.

In the context of dietary supplements and functional foods, R. miehei appears principally as a source organism for purified enzyme preparations — primarily the lipase (RML) and the protease (mucorpepsin/microbial rennet) — rather than as a whole-organism supplement. The Rhizomucor miehei lipase enzyme expressed in Aspergillus oryzae is used in the production of specialty fats, the production of existing fats from new raw materials, or new fats with improved nutritional or functional qualities.

4. Traditional and Historical Use

It is important to note that there is no documented ethnobotanical or traditional medicinal record for Rhizomucor miehei as an intentionally harvested organism used in folk or traditional medicine. Its history of use is primarily industrial and food-technological in character, rooted in mid-20th century applied mycology and enzyme technology rather than in any pre-industrial medical tradition.

By the mid-20th century, scientists and cheese producers developed microbial rennet as an alternative to animal rennet. Microbial rennet is produced by certain molds or fungi that naturally create milk-coagulating enzymes. Molds like Rhizomucor miehei or Rhizomucor pusillus can generate protease enzymes that mimic chymosin. These fungi are grown in fermentation tanks, then the enzyme is extracted and purified for use in cheesemaking. The result is a rennet that involves no animal ingredients, so it is vegetarian-friendly and also acceptable for kosher and halal cheese when properly prepared. Microbial rennets became popular because they are less expensive and avoid the supply limitations of calf stomachs.

In the 1970s, Chr. Hansen developed microbial coagulants to satisfy the industry's need for a more affordable and consistent cheesemaking component. Hannilase is Chr. Hansen's trade name for Rhizomucor miehei, a fungus that performs the same function as animal-based rennet but is fully non-animal-derived. This microbial enzyme has been a boon to cheesemakers.

The food-technological applications of R. miehei enzymes thus arose in a specific industrial context in the latter half of the 20th century and were driven by commercial and supply-chain considerations rather than by documented traditional medical practice. No verifiable pre-industrial or traditional-medicinal use of this specific organism has been identified in the peer-reviewed or regulatory literature.

5. Key Constituents and Active Compounds

Based on the existence of a large repertoire of amylolytic, proteolytic, and lipolytic genes in the genome, R. miehei has potential in the production of a variety of such enzymes. The principal biologically and commercially active compounds produced by this organism are described below.

5.1 Lipase (Rhizomucor miehei Lipase, RML; EC 3.1.1.3)

A fungal lipase (Rhizomucor miehei lipase; RML) from R. miehei is a highly versatile biocatalyst used in laboratory and commercial/industrial applications. RML is a single-chain α/β-type protein with a molecular weight of approximately 31.6 kDa, comprised of 269 amino acid residues.

The lipase from Rhizomucor miehei belongs to the family of triglyceride lipases (EC 3.1.1.3), called class 3 lipases, which are members of the α/β hydrolase superfamily that hydrolyze the ester linkages of triglycerides.

Catalytic mechanism and structural features: The catalytic center of the enzyme is made up of a constellation of three residues — His-257, Asp-203, and Ser-144 — similar in structure and function to the analogous (but not homologous) triad found in both of the known families of serine proteinases. The catalytic site is concealed under a short amphipathic helix (residues 85–91), which acts as a lid, opening the active site when the enzyme is adsorbed at the oil–water interface.

RML was the first lipase whose structure was reported, and its interfacial activation is very well known, making this enzyme a good template for modeling studies. Rhizomucor miehei lipase is probably the most used lipase obtained from fungi, and has even been used as a model for the determination of the structure of other lipases, due to the deep knowledge of its three-dimensional structure.

The lipase gene from R. miehei encodes a 1,3-specific lipase, and the enzyme is able to catalyze methanolysis of soybean oil, showing strong position specificity at the sn-1 and sn-3 positions of triglycerides.

The isoelectric point of the lipase from Rhizomucor miehei is approximately 3.8.

5.2 Aspartic Protease / Mucorpepsin (EC 3.4.23.23)

The protease from Rhizomucor miehei is the most used rennet substitute among microbial sources, holding 35% of the coagulants market share in France. It is an aspartic protease (EC 3.4.23.23) with a single polypeptide chain, and has a highly similar structural arrangement to chymosin.

The primary function of the protease in cheesemaking is to initiate the milk coagulation process through rapid and highly specific cleavage of the major milk proteins (casein). Mucorpepsin (EC 3.4.23.23) produced by Rhizomucor miehei has been proven to be a sufficient substitute for traditional rennet, due to its high specificity in splitting the Phe105-Met106 bond of κ-casein, similar to chymosin performance.

5.3 Alpha-Amylase (RmAmyA)

A novel thermostable α-amylase from Rhizomucor miehei has been expressed in Pichia pastoris. High enzyme activity of 29,794.2 U/mL was obtained through high cell-density fermentation, and liquefied starch was saccharified by this α-amylase to produce high-maltose syrup (54%). The α-amylase gene (RmAmyA) from Rhizomucor miehei was cloned and expressed in Pichia pastoris; RmAmyA showed 70% amino acid identity with the α-amylase from Rhizomucor pusillus.

5.4 Esterase

Research has also identified an esterase from R. miehei. Esterases with a broad range of non-natural substrate specificity and high stability in organic solvents are useful for a variety of industrial applications, including as additives in fat and oil processing, in laundry detergents, in synthesis of fine chemicals and pharmaceuticals, and in the manufacture of cosmetics, as well as for flavor-ester production in the food industry.

5.5 Additional Enzymatic Repertoire

The genome information of R. miehei will facilitate future studies to better understand the mechanisms of fungal thermophilic adaptation and the potential of R. miehei in industrial-scale production of thermostable enzymes. Based on the existence of a large repertoire of amylolytic, proteolytic, and lipolytic genes in the genome, R. miehei has potential in the production of a variety of such enzymes. Research has also identified xyloglucanase activity with potential applications in food processing such as yoghurt production.

6. Mechanisms of Action

6.1 Lipolytic Mechanism (Interfacial Activation)

The catalytic site of RML has been localized to the amino-terminal domain of the enzyme, which contains the catalytic triad Ser144, His257, and Asp203. Lipase has a peculiar mechanism of action called interfacial activation. In homogenous media, the active site of lipase is covered by a polypeptide chain called the lid, which plays a protective role.

The typical lid motion was assumed to follow a two-step opening mechanism that first gives rise to a semi-open conformation upon adsorption at the interface, followed by full opening of the lid upon substrate binding. Once the lid opens, the active-site catalytic triad (Ser-His-Asp) is exposed and can catalyze the hydrolysis, esterification, or transesterification of fatty acid ester bonds.

Lipases are a class of hydrolases widely distributed among microorganisms, plants, and animals. Their natural function is to catalyze the hydrolysis of glycerol ester bonds, and — due to the reversibility of the reaction — the synthesis of glycerol esters also. Most are serine hydrolases containing a serine residue in their active site, as the main residue of the classical triad Ser…His…Asp (Glu).

6.2 Proteolytic (Milk-Clotting) Mechanism

The mucorpepsin protease operates as an aspartic protease, which means its catalytic mechanism involves two aspartate residues at the active site that cooperate to mediate nucleophilic attack on the peptide bond. Mucorpepsin produced by Rhizomucor miehei has been proven to be a sufficient substitute for the traditional rennet, due to its high specificity in splitting the Phe105-Met106 bond of κ-casein similar to chymosin performance.

Some molds such as Rhizomucor miehei are able to produce proteolytic enzymes. These molds are produced in a fermenter and then specially concentrated and purified to avoid contamination with unpleasant byproducts of the mold growth.

7. Scientific Evidence by Area of Use

7.1 Dairy Processing and Cheese Production (Food Technology)

The most extensively studied and thoroughly documented application of R. miehei enzymes is as a microbial rennet substitute in cheesemaking. This represents the domain with the strongest evidence base, though it is industrial-technological rather than clinical in nature.

The protease from Rhizomucor miehei is the most used rennet substitute among microbial sources. It is an aspartic protease (EC 3.4.23.23) with a single polypeptide chain and highly similar arrangement to chymosin. Cheese produced by the protease obtained from Rhizomucor miehei was found to be the same as that from calf rennin in terms of yield and quality.

In a comparative study of Iranian Ultrafiltered White cheese produced using different blends of R. miehei microbial rennet and camel chymosin and ripened for 90 days, the results showed that pH, fat-in-dry matter, salt-in-dry matter, and protein contents of the cheeses were significantly influenced by the type and concentration of the coagulant. The difference between proteolytic activities of the two coagulants resulted in different levels of proteolysis. A direct relationship was determined between using higher concentrations of R. miehei and increasing hydrolysis of αs1-casein in the cheeses during ripening.

A key practical limitation of native R. miehei protease is its thermostability, which, while useful industrially, presents a challenge for certain cheese applications. The traditional view is that these coagulants result in bitterness and low yield in cheese, especially when aged for a long time. Over the years, however, microbial coagulants have improved greatly, largely due to the characterization and purification of secondary enzymes responsible for bitter peptide formation and non-specific proteolytic breakdown in long-aged cheeses. Thermolabile (heat-destabilized) forms of the native protease have been developed commercially to address this issue.

Evidence strength: Strong for the technological application in dairy/cheese production, supported by numerous peer-reviewed food-science studies and multiple EFSA regulatory evaluations. No clinical evidence (i.e., randomized controlled trials in humans testing health outcomes) exists for this application.

7.2 Fat and Oil Modification (Specialty Lipid Production)

The lipase from Rhizomucor miehei (RML) is a commercially available enzyme in both soluble and immobilized forms with very high activity and good stability under diverse experimental conditions. Its uses were initially oriented toward the food industry, where the enzyme has found broad application. The main uses of the enzyme in fatty acids, oils, and fats modification include hydrolysis of glycerides, transesterification, esterification, acidolysis, and interesterification.

The Rhizomucor miehei lipase enzyme expressed in Aspergillus oryzae is used in the production of specialty fats, the production of existing fats from new raw materials, and new fats with improved nutritional or functional qualities.

Several commercial products are available for this application, including Novozymes Lipozyme®, a series of lipase products (e.g., C. antarctica lipase B manufactured in A. niger or Thermomyces lanuginosus or Rhizomucor miehei lipase manufactured in A. oryzae), that are used as immobilized enzymes to reduce trans fats in margarine. Enzymatic interesterification provides a simple, efficient, and environmentally friendly way to produce margarines without the use of chemicals.

Evidence strength: Strong for the industrial application. Nutritional benefits of specialty fats produced using RML (e.g., reduced-trans-fat margarines, structured triglycerides) are established at the food-product level, but no clinical trials specifically attributing health outcomes to R. miehei-derived lipase use have been identified.

7.3 Biodiesel Production

Although the R. miehei lipase was initially produced to be used in the food industry, considerable research has focused on its application in organic chemistry, from biodiesel production to fine chemicals. The 1,3-specific lipase gene from Rhizomucor miehei expressed in Pichia pastoris produces an enzyme able to catalyze methanolysis of soybean oil, showing strong position specificity. This is not a human-health application but is included here for completeness of the scientific record.

7.4 Digestive Enzyme Supplementation (Potential Dietary Supplement Use)

In the dietary supplement market, R. miehei-derived enzymes — particularly the lipase — appear as components of multi-enzyme digestive formulas. The rationale is that the lipase's ability to hydrolyze triglycerides at the oil–water interface may augment endogenous pancreatic lipase activity, while the protease may supplement protein digestion.

Beyond cheese production, there is growing interest in the potential use of Rhizomucor miehei enzymes in other nutritional products, such as protein hydrolysates and digestive aids. However, clinical research specifically examining health benefits for humans remains limited, and claims regarding direct nutritional or therapeutic effects require further investigation.

Evidence strength: Weak to non-existent at the clinical level. No peer-reviewed, controlled human clinical trials specifically evaluating R. miehei-derived enzyme preparations as dietary supplements for digestive health, fat absorption, or related outcomes were identified. The mechanistic basis for a digestive enzyme role is biochemically plausible, but the evidence is currently limited to in vitro and food-science data.

7.5 Production of Structured Lipids / Specialty Nutritional Fats

RML is used in fine-chemical and food chemistry contexts, including enantio- or regioselective organic synthesis. One specific area is the enzymatic production of structured triglycerides — fats with defined fatty acid distributions — which have been investigated for nutritional applications such as human milk fat substitutes and clinical nutrition. RML, given its 1,3-positional specificity, is a key tool in the synthesis of such structured lipids. However, the evidence base for resultant health benefits from RML-produced structured lipids in humans derives from studies of the structured lipid products themselves, not from supplementation with the enzyme.

7.6 Alpha-Amylase Applications in Food Quality

The R. miehei α-amylase (RmAmyA) can improve the quality of Chinese steamed bread and prevent staling. This has been demonstrated in food-science research contexts but does not constitute a dietary supplement claim or clinical health finding.

8. Body Systems and Health Areas Associated with R. miehei

• Digestive system (enzymatic activity): The lipase and protease produced by R. miehei are mechanistically capable of supplementing the breakdown of dietary fats and proteins, respectively. This potential is biochemically supported but lacks human clinical trial evidence in the supplement context.
• Cardiovascular-metabolic (fat quality): The use of RML in producing specialty fats with improved fatty acid profiles (e.g., reduced trans fats in margarine) has downstream relevance to lipid nutrition and cardiovascular health at the population level through food-product reformulation.
• Immune/allergic response (allergenicity): As detailed in Section 9, EFSA panels have identified a potential for allergenicity that is relevant to individuals sensitized to mustard or certain respiratory allergens.

9. Dosage Forms and Dosages Reported in Studies

Because R. miehei-derived preparations are primarily regulated as food enzymes rather than as dietary supplement ingredients in most jurisdictions, formal dosage characterization as used in human clinical trials is largely absent. The following dosage-related data derive exclusively from regulatory toxicological evaluations:

• In toxicological safety testing, dietary concentrations of R. miehei lipase (expressed in Aspergillus oryzae) up to 1,600 mg/kg diet for up to 13 weeks caused no adverse effect in rats. At higher concentrations there were effects upon food intake, possibly arising from some irritant property of the enzyme preparation in the diet at such high levels, with consequential effects upon bodyweight and energy metabolism.
• In European populations, the dietary exposure to mucorpepsin (from R. miehei strain DSM 29547) from food was estimated at up to 0.26 mg total organic solids (TOS)/kg body weight per day.
• For mucorpepsin from R. miehei strain FRO, dietary exposure was estimated at up to approximately 0.072 mg TOS/kg body weight per day in European populations.
• For mucorpepsin from strain M19-21, dietary exposure was estimated to be up to 0.108 mg TOS/kg body weight per day in European populations.

These figures represent estimated population dietary exposures from cheese consumption, not intentional supplementation dosages. No clinical dose-finding or dose-response studies in humans for supplemental use of R. miehei enzymes were identified in the peer-reviewed literature.

10. Safety Considerations

10.1 Toxicological Safety (Regulatory Evaluations)

The safety of R. miehei-derived food enzymes has been evaluated in multiple formal toxicological studies submitted to and reviewed by the European Food Safety Authority (EFSA).

In safety testing of the R. miehei lipase enzyme preparation expressed in A. oryzae, the preparation was not found to be mutagenic either in bacterial cultures (Ames test) or in mammalian cell cultures (mouse lymphoma assay), nor did it cause chromosomal damage (human lymphocyte assay).

For mucorpepsin from strain DSM 29547, genotoxicity tests did not indicate a safety concern. Systemic toxicity was assessed by a repeated-dose 90-day oral toxicity study in rats. The Panel identified a no-observed-adverse-effect level (NOAEL) of 618 mg TOS/kg body weight per day, the highest dose tested, which when compared with the estimated dietary exposure results in a margin of exposure of at least 2,400.

For mucorpepsin from strain FRO, the NOAEL was identified at 2,000 mg TOS/kg body weight per day, the highest dose tested, resulting in a margin of exposure of at least 27,778 relative to estimated dietary exposure.

For mucorpepsin from strain M19-21, the NOAEL was 226 mg TOS/kg body weight per day, the highest dose tested, resulting in a margin of exposure of at least 2,093 relative to estimated dietary exposure.

Based on the data provided, EFSA Panels concluded that both the native and thermolabile forms of mucorpepsin food enzymes do not give rise to safety concerns under the intended conditions of use.

10.2 Allergenicity

The allergenicity profile of R. miehei-derived enzymes has been a consistent focus of EFSA safety evaluations.

The potential allergenicity of mucorpepsin from strain DSM 29547 was assessed by comparing its amino acid sequence with those of known allergens. Using greater than 35% identity in a sliding window of 80 amino acids as the criterion, three matches were found: pepsin A from Sus scrofa, an aspergillopepsin from Aspergillus fumigatus, and a lipid transfer protein (Sin a 3.01) from yellow mustard (Sinapis alba).

No information is available on oral and respiratory sensitization or elicitation reactions from this specific mucorpepsin. Pepsin from Sus scrofa as well as aspergillopepsin are associated with occupational asthma and rhinitis.

For mucorpepsin from strain FRO, five matches to known allergens were found. The Panel considered that a risk of allergic reactions upon dietary exposure to this food enzyme cannot be excluded, but is considered low, except for individuals sensitized to mustard proteins, for whom the risk will not exceed that of mustard consumption.

For mucorpepsin from strain LP-N836, four matches with respiratory allergens and one with a food allergen (mustard) were found. The Panel considered that the risk of allergic reactions upon dietary exposure, particularly in individuals sensitized to mustard proteins, cannot be excluded.

The EFSA Panel considered that, under the intended conditions of use, the risk of allergic sensitization and elicitation reactions by dietary exposure cannot be excluded but is considered low except for individuals sensitized to mustard proteins, but this risk will not exceed that of mustard consumption.

10.3 Occupational Exposure and Inhalation Risk

Exposure to enzyme dusts has long been known to cause occupational immediate hypersensitivities. Literature data concerning occupational airway sensitization due to natural and microbial rennet has been reviewed, and cases of specific airway sensitization caused by rennet could be shown clearly by several studies. Positive skin prick and challenge tests as well as specific IgE antibodies have been described, suggesting an immunological mechanism.

This occupational risk is relevant to workers in enzyme manufacturing and cheese production who may be exposed to airborne enzyme particulates, not to consumers of enzyme-containing foods or supplements.

10.4 Viable Organism Absent in Commercial Preparations

A key regulatory and safety consideration is that commercial food enzyme preparations derived from R. miehei are produced under fermentation conditions and then purified. The food enzyme is free from viable cells of the production organism. This means that consumer products do not contain living R. miehei cells, limiting the risk of infection from the production organism itself.

10.5 Pathogenic Potential of the Organism

While the enzyme preparations are safe for food use, it is relevant to note the broader biology of the organism. Rhizomucor miehei is a rare human pathogen. It has been reported from cases of pulmonary, disseminated, and cutaneous types of infection. It is more often associated with animal disease, especially bovine abortion. Rhizomucor species are among the fungi causing the group of infections referred to as zygomycosis. Although the term mucormycosis has often been used for this syndrome, zygomycosis is the preferred term for this angio-invasive disease. This pathogenic potential is clinically relevant primarily for severely immunocompromised individuals and is distinct from any risk associated with consuming purified, cell-free enzyme preparations from this organism.

10.6 Absence of Viable Cells and GMO Status of Strains

Multiple EFSA-assessed preparations are produced from non-genetically modified strains of R. miehei (e.g., strains DSM 29547, FRO, M19-21, LP-N836). However, some commercial applications involve expression of R. miehei enzyme genes in heterologous hosts such as Aspergillus oryzae or Pichia pastoris, which are classified separately by regulators. In all cases evaluated, the final food enzyme preparations were reported to be free from viable cells of the production organism.

Summary of Evidence Strength

• Cheesemaking / Milk Coagulation: Strong — multiple food-science studies, longstanding commercial use since the 1970s, multiple EFSA safety dossiers.
• Fat and Oil Modification (including trans-fat reduction in margarine): Strong — extensively characterized industrial biotechnology; nutritional benefit of the resulting products is established, but not from the enzyme supplement itself.
• Structured Lipid Production: Moderate at the food-science level; clinical evidence for resulting food products is separate from the enzyme preparation.
• Digestive Enzyme Supplementation (dietary supplement use): Weak / Insufficient — mechanistically plausible based on enzyme biochemistry; no human clinical trials identified.
• Alpha-Amylase / Carbohydrate Processing: Preliminary — demonstrated in vitro and in food-model systems; no clinical human data.

References

• DoctorFungus.org — Rhizomucor Species (taxonomy, morphology, pathogenicity)
• NCBI Taxonomy Browser — Rhizomucor miehei (Taxonomy ID: 4839)
• Walther G et al. — Updates on the Taxonomy of Mucorales with an Emphasis on Clinically Important Taxa. PMC (2020)
• Zhou P et al. — Genome sequence and transcriptome analyses of the thermophilic zygomycete fungus Rhizomucor miehei. BMC Genomics (2014)
• University of Adelaide Mycology — Rhizomucor (morphology and species descriptions)
• ScienceDirect Topics — Rhizomucor miehei Overview
• Rodrigues RC & Fernandez-Lafuente R — Lipase from Rhizomucor miehei as an industrial biocatalyst in chemical processes. Enzyme Microb Technol (2010)
• Rodrigues RC & Fernandez-Lafuente R — Lipase from Rhizomucor miehei as a biocatalyst in fats and oils modification. Enzyme Microb Technol (2010)
• Liu Y et al. — Improved production of a recombinant Rhizomucor miehei lipase expressed in Pichia pastoris and its application for conversion of microalgae oil to biodiesel. Biotechnol Biofuels (2014)
• Freitas L et al. — Lipase From Rhizomucor miehei Immobilized on Magnetic Nanoparticles: Performance in Fatty Acid Ethyl Ester Optimized Production by the Taguchi Method. Front Bioeng Biotechnol (2020)
• Li G et al. — Enhancing the Thermostability of Rhizomucor miehei Lipase with a Limited Screening Library by Rational-Design Point Mutations and Disulfide Bonds. Front Microbiol (2018)
• Suo H et al. — Improved methanol tolerance of Rhizomucor miehei lipase based on N-glycosylation within the α-helix region and its application in biodiesel production. Biotechnol Biofuels (2021)
• Tokuoka M et al. — An overview of the safety evaluation of the Rhizomucor miehei lipase enzyme. Food Addit Contam (1994)
• EFSA CEP Panel — Safety evaluation of the food enzyme mucorpepsin from Rhizomucor miehei strain DSM 29547. EFSA Journal (2022)
• EFSA CEP Panel — Safety evaluation of the food enzyme mucorpepsin from the non-genetically modified Rhizomucor miehei strain FRO. EFSA Journal (2024)
• EFSA CEP Panel — Safety evaluation of the food enzyme mucorpepsin from the non-genetically modified Rhizomucor miehei strain M19-21. EFSA Journal (2024)
• EFSA CEP Panel — Safety evaluation of the food enzyme mucorpepsin from the non-genetically modified Rhizomucor miehei strain LP-N836. EFSA Journal (2024)
• Karami M et al. — Effect of blends of camel chymosin and microbial rennet (Rhizomucor miehei) on chemical composition, proteolysis and residual coagulant activity in Iranian Ultrafiltered White cheese. PMC (2019)
• Aljammas HA et al. — Optimization of protease production from Rhizomucor miehei Rm4 isolate under solid-state fermentation. PMC (2022)
• Moroz OV et al. — Novel Inhibitory Function of the Rhizomucor miehei Lipase Propeptide and Three-Dimensional Structures of Its Complexes with the Enzyme. PMC (2019)
• Yang Z et al. — Structure-Guided Modification of Rhizomucor miehei Lipase for Production of Structured Lipids. PLOS ONE (2013)
• Brady L et al. — A serine protease triad forms the catalytic centre of a triacylglycerol lipase. Nature (1990)
• Guo Z & Xu X — Rhizomucor miehei lipase as the catalyst in the resolution of chiral compounds: an overview. Chem Phys Lipids (1999)
• Han N et al. — A novel high maltose-forming α-amylase from Rhizomucor miehei and its application in the food industry. Food Chem (2020)
• Liu Z et al. — Biochemical Characterization of a First Fungal Esterase from Rhizomucor miehei Showing High Efficiency of Ester Synthesis. PMC (2013)
• Kjærbølling I et al. — Strategies and Challenges for the Development of Industrial Enzymes Using Fungal Cell Factories. PMC (2020)
• Wikipedia — Rennet (microbial rennet section)